Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT03191149)

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change: a one-minute explainerNCT031911491 min

Biospecimen Collection trial for Advanced Lung Non-Small Cell Carcinoma (NCT03191149). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with advanced or recurrent non-small cell lung cancer containing an EGFR exon 20 insertion. At least one prior treatment for advanced disease is required; previous osimertinib is excluded. Recent checkpoint immunotherapy is also excluded.

The idea: test daily oral osimertinib at 160 milligrams. It blocks EGFR growth signaling. Researchers measure tumor response and safety in repeated 21-day cycles; scans, blood samples and heart checks monitor treatment.

This phase 2 study plans 46 patients. Zofia Piotrowska leads through ECOG-ACRIN; 215 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.